{"nctId":"NCT02325466","briefTitle":"Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes","startDateStruct":{"date":"2015-04"},"conditions":["Peripheral Artery Disease","Type 2 Diabetes"],"count":70,"armGroups":[{"label":"Aspirin/Ticagrelor placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Aspirin","Drug: Ticagrelor Placebo"]},{"label":"Aspirin/Ticagrelor","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Aspirin","Drug: Ticagrelor"]},{"label":"Aspirin Placebo/Ticagrelor","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ticagrelor","Drug: Aspirin Placebo"]}],"interventions":[{"name":"Aspirin","otherNames":["ASA"]},{"name":"Ticagrelor","otherNames":[]},{"name":"Aspirin Placebo","otherNames":["Placebo"]},{"name":"Ticagrelor Placebo","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female or male aged ≥ 35 years\n* Type 2 diabetes mellitus\n* Symptomatic PAD\n* Ankle-brachial index ≤ 0.85 or calcified blood vessels with toe-brachial index ≤ 0.6 and/or abnormal post-exercise ankle-brachial index\n* Prior surgical or percutaneous intervention of the peripheral arteries ≥12 months previously with a residual stenoses of ≥50% in a non-dilated artery.\n\nExclusion Criteria:\n\n* Subject is pregnant or breast-feeding\n* Planned revascularization or amputation\n* Known bleeding disorder\n* History of intracranial hemorrhag3\n* Considered at risk of hemorrhagic events\n* Hypersensitivity or allergic reactions to aspirin\n* Concomitant use of anticoagulants such as warfarin, dabigatran, factor Xa inhibitors or antiplatelet drugs such as clopidogrel, dipyridamole and sulfapyridine\n* Subject has a condition or circumstance which would prevent them from adhering to treatment regimens\n* Subject has active infection\n* Subject has an anemia\n* Subject has given blood or received a blood transfusion at any point during the study\n* Subject has polycythemia vera or any hyperviscosity syndrome\n* Subjects with Waldenstrom's macroglobulinemia who have an increased risk of hyperviscosity syndrome\n* Subject has history of severe liver disease, obstructive liver disease such as primary biliary cirrhosis or end-stage renal disease (eGFR \\<30 mL/min/m2)\n* Family members or employees of the investigator or study centers involved in the study\n* Subject has poor diabetes or hypertension control (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change in Low Shear Blood Viscosity","description":"Compare the effect of aspirin-ticagrelor and ticagrelor monotherapy with aspirin on blood viscosity from week 16 to baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.045","spread":"1.525"},{"groupId":"OG001","value":"-1.793","spread":"1.835"},{"groupId":"OG002","value":"-1.759","spread":"1.298"}]}]}]},{"type":"PRIMARY","title":"Mean Change in High Shear Blood Viscosity","description":"Compare the effect of aspirin-ticagrelor and ticagrelor monotherapy with aspirin on blood viscosity at week 16 to baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.165","spread":"0.318"},{"groupId":"OG001","value":"-0.228","spread":"0.469"},{"groupId":"OG002","value":"-0.231","spread":"0.360"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Peripheral Arterial Blood Flow","description":"Measure of treatment effect using pulse volume recordings of the ankle, great toe and brachial artery to calculate the ankle brachial index (ABI) and toe brachial index (TBI) at week 16 compared to baseline.\n\nABI and TBI are taken in order to determine the existence and severity of peripheral arterial disease.\n\nABI - The normal range for the ankle-brachial index is between 0.90 and 1.30. ABI \\<0.90 is abnormal: 0.41 to 0.90 indicates mild to moderate peripheral artery disease; 0.40 and lower indicates severe disease. The lower the index, the higher the chances of leg pain while exercising or limb-threatening low blood flow.\n\nTBI ≥ 0.7 is normal, TBI \\< 0.7 is abnormal.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.038","spread":"0.055"},{"groupId":"OG001","value":"0.021","spread":"0.019"},{"groupId":"OG002","value":"0.095","spread":"0.051"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.015","spread":"0.067"},{"groupId":"OG001","value":"0.032","spread":"0.038"},{"groupId":"OG002","value":"0.075","spread":"0.029"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.044","spread":"0.013"},{"groupId":"OG001","value":"0.009","spread":"0.015"},{"groupId":"OG002","value":"0.011","spread":"0.008"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.004","spread":"0.022"},{"groupId":"OG001","value":"-0.016","spread":"0.018"},{"groupId":"OG002","value":"0.036","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Microvascular Blood Flow Composite Score","description":"Measure of treatment effect using pulse volume recordings of the ankle, great toe and brachial artery to calculate the ankle brachial index and toe pressures composite score at week 16 from baseline. Composite score obtained by adding all the measurements and averaged. The score was tested by the Laser Doppler Flowmetry (LDF). Minimum score is 0 which mean no blood flow detected and there is no maximum value of the score, and higher score mean better blood flow.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.10","spread":"13.30"},{"groupId":"OG001","value":"13.64","spread":"7.34"},{"groupId":"OG002","value":"-5.23","spread":"7.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.60","spread":"11.86"},{"groupId":"OG001","value":"24.76","spread":"8.36"},{"groupId":"OG002","value":"-4.29","spread":"7.48"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":70},"commonTop":["Shortness of Breath"]}}}